Wintest
6721
Osaka Yuka Industry
4124
D. Western Therapeutics Institute
4576
Asiro
7378
Hamee
3134
(FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | (Q1)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 1.94%13.6B | 5.08%3.52B | -7.35%3.23B | 5.14%3.62B | 5.47%3.24B | 8.00%13.34B | -5.07%3.35B | 17.27%3.48B | 11.64%3.44B | 10.67%3.07B |
Cost of revenue | -3.15%7.67B | 3.48%1.99B | -15.35%1.77B | -0.64%2.01B | 0.90%1.9B | 2.90%7.92B | -11.19%1.92B | 13.79%2.09B | 6.22%2.02B | 5.26%1.89B |
Gross profit | 9.36%5.94B | 7.24%1.53B | 4.58%1.46B | 13.45%1.61B | 12.64%1.34B | 16.43%5.43B | 4.67%1.42B | 22.96%1.4B | 20.29%1.42B | 20.50%1.19B |
Operating expense | 4.15%4.82B | 11.89%1.35B | 2.44%1.18B | 0.79%1.15B | 1.06%1.15B | 12.03%4.63B | 2.84%1.2B | 13.16%1.15B | 16.94%1.14B | 16.99%1.13B |
Operating profit | 39.50%1.12B | -18.18%180M | 14.40%286M | 65.70%459M | 260.38%191M | 50.66%800M | 15.92%220M | 104.10%250M | 36.46%277M | 236.66%53M |
Net non-operating interest income (expenses) | 1.90%107M | 0 | 10.20%54M | 0 | 1.92%53M | 14.13%105M | -7.24%3M | 11.26%49M | 49.25%1M | 18.04%52M |
Non-operating interest income | 1.79%114M | -60.00%2M | 9.80%56M | -33.33%2M | 1.89%54M | 13.13%112M | 22.07%5M | 10.96%51M | 5.97%3M | 14.94%53M |
Non-operating interest expense | 0.00%7M | 0.00%2M | 0.00%2M | 0.00%2M | 0.00%1M | 0.00%7M | 132.02%2M | 4.22%2M | -7.45%2M | -51.41%1M |
Net investment income | -54.95%41M | 71.15%-15M | -736.36%-70M | 61.90%34M | -17.12%92M | 278.43%91M | -5.52%-52M | 64.08%11M | 262.50%21M | 2,367.76%111M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | -320.00%-11M | 0 | 0 | 125.00%5M | 737.76%5M | 0 | ||||
Income from associates and other participating interests | ||||||||||
Special income (charges) | -110.34%-61M | -108.00%-52M | -4M | 33.33%-2M | -200.00%-3M | -61.11%-29M | -179.02%-25M | 0 | 14.70%-3M | 50.47%-1M |
Less:Other special charges | 100.00%58M | 108.00%52M | --1M | -33.33%2M | 200.00%3M | 61.11%29M | 179.02%25M | --0 | -14.70%3M | -50.47%1M |
Less:Write off | --3M | --0 | --3M | ---- | ---- | --0 | --0 | ---- | ---- | ---- |
Other non-operating income (expenses) | -149.33%-37M | -328.00%-57M | 500.00%8M | -66.67%3M | -79.07%9M | -63.77%75M | -54.30%25M | -103.65%-2M | -78.38%9M | -23.01%43M |
Income before tax | 10.43%1.15B | -67.24%57M | -10.75%274M | 56.68%481M | 33.07%342M | 41.79%1.05B | -5.79%174M | 50.51%307M | 33.36%307M | 117.57%257M |
Income tax | -30.81%146M | -1,256.25%-185M | 14.46%95M | 62.07%94M | 162.96%142M | -0.94%211M | -78.62%16M | 36.42%83M | 130.69%58M | 3.52%54M |
Net income | 20.89%1.01B | 53.16%242M | -20.54%178M | 56.05%387M | -1.48%200M | 58.97%833M | 43.84%158M | 56.49%224M | 20.94%248M | 207.77%203M |
Net income continuous operations | 20.86%1.01B | 53.16%242M | -20.09%179M | 55.42%387M | -1.48%200M | 59.16%834M | 43.84%158M | 56.49%224M | 21.43%249M | 207.77%203M |
Noncontrolling interests | -11M | -11M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to the company | 22.21%1.02B | 60.13%253M | -20.89%178M | 56.45%388M | -1.49%199M | 59.27%833M | 44.69%158M | 57.21%225M | 20.93%248M | 207.89%202M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 22.21%1.02B | 60.13%253M | -20.89%178M | 56.45%388M | -1.49%199M | 59.27%833M | 44.69%158M | 57.21%225M | 20.93%248M | 207.89%202M |
Gross dividend payment | ||||||||||
Basic earnings per share | 25.10%227.76 | 66.72%57.67 | -16.30%41.02 | 57.63%85.39 | -1.38%43.68 | 59.07%182.06 | 43.83%34.59 | 56.78%49.01 | 20.92%54.17 | 208.86%44.29 |
Diluted earnings per share | 25.10%227.76 | 66.65%57.5153 | -17.44%40.4646 | 57.63%85.39 | -1.38%43.68 | 59.07%182.06 | 44.70%34.5127 | 56.78%49.01 | 20.92%54.17 | 208.86%44.29 |
Dividend per share | 0.00%70 | -12.50%35 | 0 | 16.67%35 | 0 | 16.67%70 | 33.33%40 | 0 | 0.00%30 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |